JNJ

Pfizer files US lawsuit against Johnson & Johnson over "anticompetitive" practices related to Remicade biosimilar
Pfizer files US lawsuit against Johnson & Johnson over "anticompetitive" practices related to Remicade biosimilar
First Word Pharma
Pfizer
JNJ
Janssen
Remicade
biosimilars
Inflectra
Flag link:
J&J, BARDA join forces to prep for pandemic flu, inking deal for vaccine and drug R&D
J&J, BARDA join forces to prep for pandemic flu, inking deal for vaccine and drug R&D
Fierce Pharma
JNJ
BARDA
pandemic flu
vaccines
R&D
Flag link:
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Motley Fool
JNJ
Remicade
Stelara
drug pricing
Imbruvica
Xarelto
Darzalex
devices
consumer health
Flag link:
Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
Investors Business Daily
Amgen
Eli Lilly
JNJ
Exelixis
biotech
Theravance
Bavarian Nordic
Agios
Biohaven Pharmaceuticals
Progenics
Flag link:
J&J moves away from hep C due to rival drugmakers' cures
J&J moves away from hep C due to rival drugmakers' cures
BioPharma Dive
JNJ
hepatitis C
JNJ-4178
R&D
hepatitis B
Flag link:
GSK, JnJ and Sanofi: potential buyers of Merck KGaA’s Consumer Health business
GSK, JnJ and Sanofi: potential buyers of Merck KGaA’s Consumer Health business
GoInPharma
GSK
JNJ
Sanofi
Merck KGaA
consumer health
M&A
Flag link:
AbbVie and Pfizer hover at top, J&J Stelara surges in August TV pharma ad spend
AbbVie and Pfizer hover at top, J&J Stelara surges in August TV pharma ad spend
Fierce Pharma
AbbVie
Pfizer
JNJ
drug ads
television ads
Flag link:
J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market
J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market
Endpoints
JNJ
Achillion
hepatitis C
odalasvir
ACH-3102
Flag link:
J&J’s Ethicon hit with $57m verdict in pelvic mesh case
J&J’s Ethicon hit with $57m verdict in pelvic mesh case
Mass Device
JNJ
Ethicon
pelvic mesh
devices
Flag link:
Takeda, Johnson & Johnson and more join Clara Health's Boston-based patient empowerment push
Takeda, Johnson & Johnson and more join Clara Health's Boston-based patient empowerment push
Fierce Pharma
Takeda
JNJ
Clara Health
Amylyx Pharmaceuticals
patients
Boston
Flag link:
Texas Judge delays J&J Pinnacle hip implant bellwether trial
Texas Judge delays J&J Pinnacle hip implant bellwether trial
Mass Device
JNJ
Pinnacle Hip
hip implants
devices
Texas
DePuy Ortho
Flag link:
Neurotoxicity kills a CAR-T rival pushed by J&J, MacroGenics in $700M deal
Neurotoxicity kills a CAR-T rival pushed by J&J, MacroGenics in $700M deal
Endpoints
JNJ
CAR-T
Macrogenics
MGD011
Flag link:
Boston Scientific, J&J win Pentagon award for supporting employed service members
Boston Scientific, J&J win Pentagon award for supporting employed service members
Mass Device
Boston Scientific
JNJ
devices
military
Flag link:
J&J Investors Should Ignore The Noise Of Cancer Lawsuits For Now
J&J Investors Should Ignore The Noise Of Cancer Lawsuits For Now
Seeking Alpha
JNJ
ovarian cancer
Flag link:
Best Pharma Stocks Based on R&D Spending
Best Pharma Stocks Based on R&D Spending
Motley Fool
R&D
pharma stocks
Roche
Novartis
Pfizer
JNJ
Merck
Flag link:
3 Most Promising Cancer Drugs in Late-Stage Development
3 Most Promising Cancer Drugs in Late-Stage Development
Motley Fool
Eli Lilly
abemaciclib
advanced breast cancer
Incyte
epacadostat
Imbruvica
JNJ
prostate cancer
Flag link:
Record $417M award in lawsuit linking baby powder to cancer
Record $417M award in lawsuit linking baby powder to cancer
Yahoo/AP
JNJ
Flag link:
Bayer, J&J win third U.S. trial over Xarelto bleeding risk
Bayer, J&J win third U.S. trial over Xarelto bleeding risk
Yahoo/Reuters
Bayer
JNJ
Xarelto
bloodthinners
Flag link:
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
Fierce Pharma
patents
AbbVie
Humira
Pfizer
Lipitor
Norvasc
GSK
Advair
Sanofi
Lantus
JNJ
Remicade
AstraZeneca
Crestor
Nexium
Amgen
Neulasta
Novartis
Diovan
Flag link:
J&J’s Alex Gorsky reverses course and jumps ship — just as Trump scuttles top CEO groups
J&J’s Alex Gorsky reverses course and jumps ship — just as Trump scuttles top CEO groups
Endpoints
JNJ
Alex Gorsky
Pharma CEOs
Donald Trump
Flag link: